BioCatalyst

GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] — catalyst calendar

1 verified catalyst event(s) referencing GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®], each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-15
in 3mo
ESTIMATED
 READOUT
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab
Phase 1/2 · Solid Tumor, Adult, Refractory Cancer
 GV20 Therapeutics GV20-0251, GV20-0251, GV20-0251 and Pemb ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.